Ligand (LGND) Breakout! Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout!

LGND 189.09

-8.5%

Jan 13 3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Andrew H who wrote (3902)	7/8/1997 9:59:00 AM
From: Henry Niman	of 32384

Andy, PIR (First Call) seems to have found "believers". They seem to think that H&Q upgraded LGND to a STRONG BUY. Consequently, they list LGND as having 5 recs, all in the STRONG BUY category, giving LGND a perfect score of 1.0. This rating puts LGND in the #1 position among Biotechs. Here's their top five (I think they set a minimum # of recs at 5): Analysts' Highest-, Lowest-Rated Stocks: Medical & Biotech Professional Investor Report ~ June 30, 1997 ~ 8:33 am EST This is a daily ranking of the five highest-rated stocks and the five lowest-rated stocks within the Medical & Biotech industry, based on analysts' recommendations contributed within the past month to First Call's database. To be included on the list, a company must be rated by at least five analysts. Also included in the list are First Call analysts' estimates for the companies' current quarters. Estimates are operating income per share based on a survey of analysts. First Call Consensus Recommendation Scale 1.0-2.4 = Buy 2.5-3.4 = Hold 3.5-5.0 = Sell Most Attractive Issues ---------------------- Latest # Analysts First Call # Analysts Consensus Covering EPS Estimate Covering --------- ---------- ------------ ---------- (Q: LGND) 1.0 5 ($0.32) 2Q 3 (Q: ALKS) 1.2 6 ($0.23) 1Q 1 (Q: INCY) 1.3 6 $0.15 2Q 5 (Q: PRXL) 1.3 7 $0.16 4Q 8 (Q: AGPH) 1.3 9 ($0.27) 4Q 9 Least Attractive Issues ----------------------- Latest # Analysts First Call # Analysts Consensus Covering EPS Estimate Covering --------- ---------- ------------ ---------- (Q: SMTG) 3.2 5 ($0.25) 4Q 2 (Q: URMD) 3.0 7 ($0.34) 2Q 6 (Q: IMNX) 2.7 9 ($0.22) 2Q 6 (Q: CHIR) 2.6 14 $0.11 2Q 12 (Q: MYCO) 2.6 8 $0.33 3Q 7 (END) DOW JONES NEWS 06-30-97 8:24 AM EDT

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next